Miller Anestesia

471. Bhana N, Goa KL, McClellan KJ: Dexmedetomi-

dine. Drugs 59:263–268, 2000.

472. Virtanen R, Savola JM, Saano V, Nyman L: Charac-

terization of the selectivity, specificity and potency

of medetomidine as an alpha 2-adrenoceptor

agonist. Eur J Pharmacol 150:9–14, 1988.

473. Dyck JB, Maze M, Haack C, et al: Computer-con-

trolled infusion of intravenous dexmedetomidine

hydrochloride in adult human volunteers. Anesthe-

siology 78:821–828, 1993.

474. Dyck JB, Maze M, Haack C, et al: The pharmacoki-

netics and hemodynamic effects of intravenous and

intramuscular dexmedetomidine hydrochloride in

adult human volunteers. Anesthesiology 78:813–

820, 1993.

475. De Wolf AM, Fragen RJ, Avram MJ, et al: The phar-

macokinetics of dexmedetomidine in volunteers

with severe renal impairment. Anesth Analg

93:1205–1209, 2001.

476. Venn RM, Karol MD, Grounds RM: Pharmacoki-

netics of dexmedetomidine infusions for sedation

of postoperative patients requiring intensive caret.

Br J Anaesth 88:669–675, 2002.

477. Aantaa R, Jalonen J: Perioperative use of alpha

adrenoceptor agonists and the cardiac patient. Eur

J Anaesthesiol 23:361–372, 2006.

478. Paris A,Tonner PH: Dexmedetomidine in anaesthe-

sia. Curr Opin Anaesthesiol 18:412–418, 2005.

479. Guo TZ, Jiang JY, Buttermann AE, Maze M: Dex-

medetomidine injection into the locus ceruleus

produces antinociception. Anesthesiology 84:873–

881, 1996.

480. Venn RM, Bradshaw CJ, Spencer R, et al: Prelimi-

nary UK experience of dexmedetomidine, a novel

agent for postoperative sedation in the intensive

care unit. Anaesthesia 54:1136–1142, 1999.

481. Venn RM, Hell J, Grounds RM: Respiratory effects

of dexmedetomidine in the surgical patient requi-

ring intensive care. Crit Care 4:302–308, 2000.

482. Kress JP, Pohlman AS, O’Connor MF, Hall JB: Daily

interruption of sedative infusions in critically ill

patients undergoing mechanical ventilation. N Engl

J Med 342:1471–1477, 2000.

483. Nelson LE, Lu J, Guo T, et al: The alpha

-adrenocep-

tor agonist dexmedetomidine converges on an

endogenous sleep-promoting pathway to exert its

sedative effects. Anesthesiology 98:428–436, 2003.

484. Nacif-Coelho C, Correa-Sales C, Chang LL, Maze

M: Perturbation of ion channel conductance alters

the hypnotic response to the alpha 2-adrenergic

agonist dexmedetomidine in the locus coeruleus of

the rat. Anesthesiology 81:1527–1534, 1994.

485. Angst MS, Ramaswamy B, Davies MF, Maze M:

Comparative analgesic and mental effects of increa-

sing plasma concentrations of dexmedetomidine

and alfentanil in humans. Anesthesiology 101:744–

752, 2004.

486. Ramsay MA, Luterman DL: Dexmedetomidine as a

total intravenous anesthetic agent. Anesthesiology

101:787–790, 2004.

487. Aho M, Erkola O, Kallio A, et al: Comparison of

dexmedetomidine and midazolam sedation and

antagonism of dexmedetomidine with atipamezole.

J Clin Anesth 5:194–203, 1993.

488. Reid K, Hayashi Y, Guo TZ, et al: Chronic adminis-

tration of an alpha 2 adrenergic agonist desensitizes

rats to the anesthetic effects of dexmedetomidine.

Pharmacol Biochem Behav 47:171–175, 1994.

489. Maccioli GA: Dexmedetomidine to facilitate drug

withdrawal. Anesthesiology 98:575–577, 2003.

490. Davies MF, Haimor F, Lighthall G, Clark JD: Dex-

medetomidine fails to cause hyperalgesia after ces-

sation of chronic administration. Anesth Analg

96:195–200, 2003.

491. Hayashi Y, Guo TZ, Maze M: Hypnotic and analge-

sic effects of the alpha 2-adrenergic agonist dexme-

detomidine in morphine-tolerant rats. Anesth

Analg 83:606–610, 1996.

492. Asano T, Dohi S, Ohta S, et al: Antinociception by

epidural and systemic alpha(2)-adrenoceptor ago-

nists and their binding affinity in rat spinal cord and

brain. Anesth Analg 90:400–407, 2000.

493. Tryba M, Gehling M: Clonidine—a potent analge-

sic adjuvant. Curr Opin Anaesthesiol 15:511–517,

2002.

494. Eisenach JC, De Kock M, Klimscha W: Alpha(2)-

adrenergic agonists for regional anesthesia: A clini-

cal review of clonidine (1984-1995).Anesthesiology

85:655–674, 1996.

495. Eisenach JC, Shafer SL, Bucklin BA, et al: Pharma-

cokinetics and pharmacodynamics of intraspinal

dexmedetomidine in sheep. Anesthesiology

80:1349–1359, 1994.

496. Aho MS, Erkola OA, Scheinin H, et al: Effect of

intravenously administered dexmedetomidine on

pain after laparoscopic tubal ligation. Anesth Analg

73:112–118, 1991.

497. Hall JE, Uhrich TD, Barney JA, et al: Sedative,

amnestic, and analgesic properties of small-dose

dexmedetomidine infusions. Anesth Analg 90:699–

705, 2000.

498. Cortinez LI, Hsu YW, Sum-Ping ST, et al: Dexme-

detomidine pharmacodynamics, part II: Crossover

comparison of the analgesic effect of dexmedetomi-

dine and remifentanil in healthy volunteers. Anes-

thesiology 101:1077–1083, 2004.

499. Maier C, Steinberg GK, Sun GH, et al: Neuropro-

tection by the alpha 2-adrenoreceptor agonist dex-

medetomidine in a focal model of cerebral ischemia.

Anesthesiology 79:306–312, 1993.

500. Hoffman WE, Kochs E, Werner C, et al: Dexmede-

tomidine improves neurologic outcome from

incomplete ischemia in the rat: Reversal by the

alpha 2-adrenergic antagonist atipamezole. Anes-

thesiology 75:328–332, 1991.

501. Kuhmonen J, Pokorny J, Miettinen R, et al: Neuro-

protective effects of dexmedetomidine in the gerbil

hippocampus after transient global ischemia. Anes-

thesiology 87:371–377, 1997.

502. Engelhard K,Werner C, Kaspar S, et al: Effect of the

alpha2-agonist dexmedetomidine on cerebral neu-

rotransmitter concentrations during cerebral ische-

mia in rats. Anesthesiology 96:450–457, 2002.

503. Talke P, Bickler PE: Effects of dexmedetomidine on

hypoxia-evoked glutamate release and glutamate

receptor activity in hippocampal slices.Anesthesio-

logy 85:551–557, 1996.

504. Talke P, Tong C, Lee HW, et al: Effect of dexmede-

tomidine on lumbar cerebrospinal fluid pressure in

humans. Anesth Analg 85:358–364, 1997.

505. Karlsson BR, Forsman M, Roald OK, et al: Effect of

dexmedetomidine, a selective and potent alpha

2-agonist, on cerebral blood flow and oxygen con-

sumption during halothane anesthesia in dogs.

Anesth Analg 71:125–129, 1990.

506. Zornow MH, Fleischer JE, Scheller MS, et al: Dex-

medetomidine, an alpha 2-adrenergic agonist,

decreases cerebral blood flow in the isoflurane-

anesthetized dog. Anesth Analg 70:624–630, 1990.

507. Zornow MH, Maze M, Dyck JB, Shafer SL: Dexme-

detomidine decreases cerebral blood flow velocity

in humans. J Cereb Blood Flow Metab 13:350–353,

1993.

508. Bekker A, Sturaitis MK: Dexmedetomidine for neu-

rological surgery. Neurosurgery 57:1–10, 2005.

509. Drummond JC, Dao AV, Roth DM, et al: Effect of

dexmedetomidine on cerebral blood flow velocity,

cerebral metabolic rate, and carbon dioxide res-

ponse in normal humans. Anesthesiology 108:225–

232, 2008.

510. Mirski MA, Rossell LA, McPherson RW, Traystman

RJ: Dexmedetomidine decreases seizure threshold

in a rat model of experimental generalized epilepsy.

Anesthesiology 81:1422–1428, 1994.

511. Halonen T, Kotti T, Tuunanen J, et al: Alpha 2-adre-

noceptor agonist, dexmedetomidine, protects

against kainic acid-induced convulsions and neuro-

nal damage. Brain Res 693:217–224, 1995.

512. Weinger MB, Segal IS, Maze M: Dexmedetomidine,

acting through central alpha-2 adrenoceptors, pre-

vents opiate-induced muscle rigidity in the rat.

Anesthesiology 71:242–249, 1989.

513. Schmucker P, van Ackern K, Franke N, et al: [Effect

of the intravenous administration of lormetazepam

on hemodynamics and arterial blood gases in

patients with coronary heart disease]. Anaesthetist

31:557–563, 1982.

514. Karhuvaara S, Kallio A, Koulu M, et al: No involve-

ment of alpha 2-adrenoceptors in the regulation of

basal prolactin secretion in healthy men. Psycho-

neuroendocrinology 15:125–129, 1990.

515. Ebert TJ, Hall JE, Barney JA, et al: The effects of

increasing plasma concentrations of dexmedetomi-

dine in humans. Anesthesiology 93:382–394, 2000.

516. Yung-Wei H, Robertson K,Young C, et al: Compare

the respiratory effects of remifentanil and dexme-

detomidine. Anesthesiology 95:A1357, 2001.

517. Arain SR, Ebert TJ: The efficacy, side effects, and

recovery characteristics of dexmedetomidine versus

propofol when used for intraoperative sedation.

Anesth Analg 95:461–466, 2002.

518. Hsu YW, Cortinez LI, Robertson KM, et al: Dexme-

detomidine pharmacodynamics, part I: Crossover

comparison of the respiratory effects of dexmede-

tomidine and remifentanil in healthy volunteers.

Anesthesiology 101:1066–1076, 2004.

519. Lou YP, Franco-Cereceda A, Lundberg JM: Variable

alpha 2-adrenoceptor-mediated inhibition of bron-

choconstriction and peptide release upon activation

of pulmonary afferents. Eur J Pharmacol 210:173–

181, 1992.

520. Hogue CW Jr, Talke P, Stein PK, et al: Autonomic

nervous system responses during sedative infusions

of dexmedetomidine. Anesthesiology 97:592–598,

2002.

521. Riker RR, Fraser GL: Adverse events associated

with sedatives, analgesics, and other drugs that

provide patient comfort in the intensive care unit.

Pharmacotherapy 25:8S–18S, 2005.

522. Roekaerts P, Prinzen F, Willingers H: The effect of

dexmedetomidine on systemic haemodynamics,

regional myocardial function and blood flow during

coronary artery stenosis in acute anaesthetized

dogs. J Cardiothorac Anesth 8:58, 1994.

523. Willigers HM, Prinzen FW, Roekaerts PM, et al:

Dexmedetomidine decreases perioperative myocar-

dial lactate release in dogs. Anesth Analg 96:657–

664, 2003.

524. Nishina K, Mikawa K, Uesugi T, et al: Efficacy of

clonidine for prevention of perioperative myocar-

dial ischemia: A critical appraisal and meta-analysis

of the literature. Anesthesiology 96:323–329, 2002.

525. Wallace AW, Galindez D, Salahieh A, et al: Effect of

clonidine on cardiovascular morbidity and morta-

lity after noncardiac surgery. Anesthesiology

101:284–293, 2004.

526. Venn M, Newman J, Grounds M: A phase II study

to evaluate the efficacy of dexmedetomidine for

sedation in the medical intensive care unit. Inten-

sive Care Med 29:201–207, 2003.

527. Karhuvaara S, Kallio A, Salonen M, et al: Rapid

reversal of alpha 2-adrenoceptor agonist effects by

Anestésicos intravenosos

533

Sección II

Farmacología y anestesia